Clinical Trial Update: The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update discusses a study evaluating Ultra Q10 plus L-carnitine in myelodysplastic syndrome (Phase 2/Phase 3) with the status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• L-carnitine (L-carnitine)
• Ultra Q10 (ubiquinone)

Snippet

Sponsor: Kaplan Medical Center | Conditions: Myelodysplastic Syndrome | Phase 2, Phase 3 | Status: UNKNOWN